The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered. Reporting of adverse events is a critical postmarketing activity. METHODS We report findings in 23 patients who presented with thrombosis and… Continue reading Pathologic Antibodies to #Platelet Factor 4 after ChAdOx1 #nCoV-19 #Vaccination
Tag: Thrombosis
American Society of Hematology 2021 guidelines for management of venous #thromboembolism: prevention and treatment in patients with #cancer
Venous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and… Continue reading American Society of Hematology 2021 guidelines for management of venous #thromboembolism: prevention and treatment in patients with #cancer
#Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized #COVID-19 patients
Patients with coronavirus disease-19 (COVID-19) are at high risk for thrombotic arterial and venous occlusions. However, bleeding complications have also been observed in some patients. Understanding the balance between coagulation and fibrinolysis will help inform optimal approaches to thrombosis prophylaxis and potential utility of fibrinolytic-targeted therapies. 118 hospitalized COVID-19 patients and 30 healthy controls were… Continue reading #Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized #COVID-19 patients
#Neutrophil more than #platelet activation associates with #thrombotic complications in #COVID-19 patients
SARS-CoV-2 infection is associated with hypercoagulability which predisposes to venous thromboembolism (VTE). We analyzed platelet and neutrophil activation in COVID-19 patients and their association with VTE. Methods Hospitalized COVID-19 patients and age- and sex-matched healthy controls were studied. Platelet and leukocyte activation, neutrophil extracellular traps (NETs), and matrix metalloproteinase-9 (MMP-9), a neutrophil-released enzyme, were measured.… Continue reading #Neutrophil more than #platelet activation associates with #thrombotic complications in #COVID-19 patients
#Prothrombotic autoantibodies in serum from patients hospitalized with #COVID-19
Patients with COVID-19 are at high risk for thrombotic arterial and venous occlusions. Lung histopathology often reveals fibrin-based occlusions in the small blood vessels of patients who succumb to the disease. Antiphospholipid syndrome is an acquired and potentially life-threatening thrombophilia in which patients develop pathogenic autoantibodies targeting phospholipids and phospholipid-binding proteins (aPL antibodies). Case series… Continue reading #Prothrombotic autoantibodies in serum from patients hospitalized with #COVID-19
American Society of Hematology 2020 guidelines for management of venous #thromboembolism: treatment of deep vein #thrombosis and pulmonary #embolism
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually.. ..Strong recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio… Continue reading American Society of Hematology 2020 guidelines for management of venous #thromboembolism: treatment of deep vein #thrombosis and pulmonary #embolism
Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial
Patients with unprovoked (i.e., without the presence of apparent transient risk factors such as recent surgery) venous thromboembolism (VTE) are at risk of recurrence if anticoagulants are stopped after 3–6 months, yet their risk remains heterogeneous. Thus, prolonging anticoagulant treatment should be considered in high-risk patients, whereas stopping is likely preferred in those with a… Continue reading Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial
Post-Discharge Prophylaxis With #Rivaroxaban Reduces Fatal and Major #Thromboembolic Events in Medically Ill Patients
Hospitalized acutely ill medical patients are at risk for fatal and major thromboembolic events. Whether use of extended-duration primary thromboprophylaxis can prevent such events is unknown.. ..Medically ill patients with a baseline creatinine clearance ≥50 ml/min were randomized in a double-blind fashion to rivaroxaban 10 mg or placebo daily at hospital discharge for 45 days.… Continue reading Post-Discharge Prophylaxis With #Rivaroxaban Reduces Fatal and Major #Thromboembolic Events in Medically Ill Patients
Clinical Effectiveness and Safety of #Aspirin for Venous #Thromboembolism Prophylaxis After Total Hip and Knee Replacement
Patients undergoing total hip replacement (THR) and total knee replacement (TKR) receive venous thromboembolism (VTE) pharmacoprophylaxis. It is unclear which anticoagulant is preferable. Observational data suggest aspirin provides effective VTE prophylaxis.. ..The RR of VTE after THR and TKR was 1.12 (95% CI, 0.78-1.62) for aspirin compared with other anticoagulants. Comparable findings were observed for… Continue reading Clinical Effectiveness and Safety of #Aspirin for Venous #Thromboembolism Prophylaxis After Total Hip and Knee Replacement
2 Medical News 